JP2006523699A - モンテルカストナトリウムの多形形態 - Google Patents

モンテルカストナトリウムの多形形態 Download PDF

Info

Publication number
JP2006523699A
JP2006523699A JP2006509926A JP2006509926A JP2006523699A JP 2006523699 A JP2006523699 A JP 2006523699A JP 2006509926 A JP2006509926 A JP 2006509926A JP 2006509926 A JP2006509926 A JP 2006509926A JP 2006523699 A JP2006523699 A JP 2006523699A
Authority
JP
Japan
Prior art keywords
montelukast sodium
acetonitrile
monosorbate
montelukast
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006509926A
Other languages
English (en)
Japanese (ja)
Inventor
チヨウ，チユン−ホン
ゲンツラー，マイケル・ビー
マイケルズ，ジエームズ・エヌ
ウー，マイケル・クオチエ
バザン，シンシア
クラ，ソフイー−ドロテー
ダルトン，チヤド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2006523699A publication Critical patent/JP2006523699A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
JP2006509926A 2003-04-15 2004-04-12 モンテルカストナトリウムの多形形態 Pending JP2006523699A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46294103P 2003-04-15 2003-04-15
PCT/US2004/011211 WO2004091618A1 (en) 2003-04-15 2004-04-12 Polymorphic form of montelukast sodium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010000907A Division JP2010132668A (ja) 2003-04-15 2010-01-06 モンテルカストナトリウムの多形形態

Publications (1)

Publication Number Publication Date
JP2006523699A true JP2006523699A (ja) 2006-10-19

Family

ID=33300016

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006509926A Pending JP2006523699A (ja) 2003-04-15 2004-04-12 モンテルカストナトリウムの多形形態
JP2010000907A Withdrawn JP2010132668A (ja) 2003-04-15 2010-01-06 モンテルカストナトリウムの多形形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010000907A Withdrawn JP2010132668A (ja) 2003-04-15 2010-01-06 モンテルカストナトリウムの多形形態

Country Status (7)

Country Link
US (1) US7560559B2 (enExample)
EP (1) EP1633357A4 (enExample)
JP (2) JP2006523699A (enExample)
CN (1) CN1852713B (enExample)
AU (1) AU2004229507B2 (enExample)
CA (1) CA2522053C (enExample)
WO (1) WO2004091618A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074935A1 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
EP1709002A2 (en) * 2004-01-30 2006-10-11 Teva Pharmaceutical Industries Ltd. Montelukast sodium polymorphs
EP1646612B1 (en) 2004-04-21 2009-07-01 Teva Pharmaceutical Industries Ltd Processes for preparing montelukast sodium
EP1831171A4 (en) * 2004-11-19 2010-09-15 Matrix Lab Ltd PROCESS FOR THE PREPARATION OF NEW MONTELUKAST SODIUM AMORPHOUS
JP2008510840A (ja) 2005-07-05 2008-04-10 テバ ファーマシューティカル インダストリーズ リミティド モンテルカストの精製
US8178680B2 (en) * 2005-12-13 2012-05-15 Msn Laboratories Limited Process for the preparation of Montelukast and its pharmaceutically acceptable salts
US8115004B2 (en) * 2006-11-20 2012-02-14 Msn Laboratories Limited Process for pure montelukast sodium through pure intermediates as well as amine salts
WO2010064257A1 (en) * 2008-12-01 2010-06-10 Innogent Laboratories Private Limited Novel intermediates for producing [r-(e)]-1-[[[1-[3-[2-(7- chloro -quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy- methylethyl) phenyl]propyl]thio] methyl] cyclopropaneacetic acid, monosodium salt and process thereof
EP2287154A1 (en) 2009-07-14 2011-02-23 KRKA, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast
WO2011033470A1 (en) 2009-09-16 2011-03-24 Ranbaxy Laboratories Limited Crystalline form of montelukast sodium
US20110195042A1 (en) * 2010-02-10 2011-08-11 Thomas Edward Huetter Compositions, Methods and Kits Useful for Treating a Respiratory Symptom
WO2011121091A1 (en) 2010-03-31 2011-10-06 Krka, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein
KR100990046B1 (ko) 2010-07-30 2010-10-26 동국제약 주식회사 신규한 몬테루카스트 4-할로 벤질아민염 및 이를 이용한 몬테루카스트 나트륨염의 제조방법
US8471030B2 (en) 2010-12-06 2013-06-25 Orochem Technologies Inc. Purification of montelukast using simulated moving bed
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
CN104055741B (zh) * 2013-03-18 2017-02-15 青岛大学 一种孟鲁司特钠片剂及其制备方法
CN104649968B (zh) * 2013-11-25 2017-03-15 天津汉瑞药业有限公司 一种孟鲁司特钠倍半水合物化合物
JP2017503814A (ja) 2014-01-22 2017-02-02 タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ 部分的コントロール状態の重症喘息またはコントロール不良状態の重症喘息のｐｄｅ４インヒビターを用いた（およびロイコトリエン調節薬と組み合わせて用いた）治療
CN107049940A (zh) * 2017-03-10 2017-08-18 重庆西南医院 一种促进孟鲁司特钠经直肠吸收的促进剂及其使用方法
CN107162969A (zh) * 2017-07-05 2017-09-15 成都亿知科技有限公司 孟鲁司特钠晶体及其制备方法和药物组合物
EP3846792A4 (en) 2018-09-06 2022-10-12 Innopharmascreen Inc. METHODS AND COMPOSITIONS FOR TREATING ASTHMA OR PARKINSON'S DISEASE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022987A1 (en) * 1995-01-23 1996-08-01 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
JPH09507235A (ja) * 1993-12-28 1997-07-22 メルク エンド カンパニー インコーポレーテッド ロイコトリエン拮抗物質の調製方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5869673A (en) * 1997-02-28 1999-02-09 Merck & Co., Inc. Process for 3-(2-(7-chloro-2-quinolinyl)ethenyl) - benzaldehyde
US5952347A (en) * 1997-03-13 1999-09-14 Merck & Co., Inc. Quinoline leukotriene antagonists
EP1119372A1 (en) * 1998-10-09 2001-08-01 Schering Corporation Composition and method for treating allergic diseases
AU2002256967A1 (en) * 2000-10-30 2002-09-12 Schering Corporation Treating or reducing the risk of cardiovascular disease
AU2003209043A1 (en) * 2002-02-07 2003-09-02 Dr. Reddy's Laboratories Ltd. Novel anhydrous amorphous forms of montelukast sodium salt

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09507235A (ja) * 1993-12-28 1997-07-22 メルク エンド カンパニー インコーポレーテッド ロイコトリエン拮抗物質の調製方法
WO1996022987A1 (en) * 1995-01-23 1996-08-01 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid

Also Published As

Publication number Publication date
US20060194838A1 (en) 2006-08-31
US7560559B2 (en) 2009-07-14
CN1852713B (zh) 2010-12-01
WO2004091618A1 (en) 2004-10-28
AU2004229507A1 (en) 2004-10-28
EP1633357A1 (en) 2006-03-15
JP2010132668A (ja) 2010-06-17
AU2004229507B2 (en) 2008-12-18
CN1852713A (zh) 2006-10-25
EP1633357A4 (en) 2010-02-10
CA2522053A1 (en) 2004-10-28
CA2522053C (en) 2010-06-29

Similar Documents

Publication Publication Date Title
JP2010132668A (ja) モンテルカストナトリウムの多形形態
MX2014009544A (es) Sal de hemisulfato de n-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6 ,7,8,9-tetrahidro-5h-ciclohepta[b]piridin-9-il-4-(2-oxo-2,3-dihid ro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1-carboxilato.
KR20080114723A (ko) 비페닐-2-일카르밤산 1-〔2-（2-클로로-4-｛〔（ｒ）-2-히드록시-2-（8-히드록시-2-옥소-1,2-디히드로퀴놀린-5-일）에틸아미노〕메틸｝-5-메톡시페닐카르바모일）에틸〕피페리딘-4-일 에스테르의 석신산 염 및 이의 폐질환 치료를 위한 용도
CN112135832A (zh) 化合物的晶型和制备化合物的晶型的方法
CN108727347A (zh) 一种阿片样物质受体(mor)激动剂的晶型及其制备方法
AU2018303293A1 (en) Amorphous form of vilanterol trifenatate and processes for the preparation thereof
CN111943962A (zh) 咪唑并噁嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法
JP6674967B2 (ja) 化合物 （ｓ）−３−｛４−［５−（２−シクロペンチル−６−メトキシ−ピリジン−４−イル）−［１，２，４］オキサジアゾール−３−イル］−２−エチル−６−メチル−フェノキシ｝−プロパン−１，２−ジオールの結晶形
JP2013510176A (ja) （１ｓ，２ｒ）−２−（アミノメチル）−ｎ，ｎ−ジエチル−１−フェニルシクロプロパンカルボキサミドの新規結晶形態
BRPI0712915A2 (pt) sal de xinafoato de um composto de 5-oxazal-2-il-quinolina substituìdo
JP7049270B2 (ja) ラクトースと臭化グリコピロニウムの結晶性医薬品共結晶
JPWO2004020433A1 (ja) 新規結晶
JP2025514863A (ja) Ｐｄｅ４阻害剤の新規結晶形態
JP7627683B2 (ja) Ｎ－Ｔｅｒｔ－ブチル－４［［２－（５－クロロ－２－ヒドロキシ－フェニル）アセチル］アミノ］ピリジン－２－カルボキサミドの固体形態
JP2018531249A6 (ja) ホスネツピタントの結晶形
JP2024506140A (ja) 抗インフルエンザウイルス化合物の結晶形及びその製造方法と用途
JP2018531249A (ja) ホスネツピタントの結晶形
WO2025237335A1 (zh) 一种葫芦脲衍生物的可药用盐、其结晶形式及用途
TW202421127A (zh) ５Ｈ－吡咯并〔２，３－ｄ〕嘧啶－６（７Ｈ）－酮及其鹽體之結晶
WO2024255834A1 (zh) 吡啶氮氧化合物的盐型、共晶及其制备方法和应用
CN121175304A (zh) 胺基喹唑啉衍生物的盐
CN116283957A (zh) 唑吡坦水合物及其制备方法
WO2018084817A2 (en) A new form of active agent
CN104797579A (zh) 噻托溴铵溶剂化物的稳定化

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090930

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110222

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110301

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110802

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110802